Targeting AKT1-E17K and the PI3K/AKT pathway with an allosteric AKT inhibitor, ARQ 092

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Yu, Yi ^a   Savage, Ronald E ^a   Eathiraj, Sudharshan ^a   Meade, Justin ^b   Wick, Michael J ^b   Hall, Terence ^a   Abbadessa, Giovanni ^a   Schwartz, Brian ^a  

^a ARQULE INC   (United States)

^b South Texas Accelerated Research Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARQ 092; ARQ 751; PACLITAXEL; PROTEIN KINASE B INHIBITOR; TRAMETINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; AMINOPYRIDINE DERIVATIVE; IMIDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

AKT1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENDOMETRIAL CANCER CELL LINE; ENZYME INHIBITION; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MELANOMA; MOUSE; NONHUMAN; PI3K GENE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; 3T3 CELL LINE; ALLOSTERISM; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; GENETICS; HEK293 CELL LINE; METABOLISM; PROTEIN TRANSPORT; SECOND MESSENGER; TUMOR CELL LINE;

ALLOSTERIC REGULATION; AMINOPYRIDINES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; HEK293 CELLS; HUMANS; IMIDAZOLES; MICE; NIH 3T3 CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; SECOND MESSENGER SYSTEMS;

EID: 84949035119     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140479     Document Type: Article

References (62)

1. Staal SP, Hartley JW, Rowe WP. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci U S A. 1977; 74(7): 3065-67. PMID: 197531
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and Metabolism. Nat Rev Genet. 2006; 7(8): 606-19. PMID: 16847462
3. Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell. 2007; 129(7): 1261-74. PMID: 17604717
4. Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem. 2004; 279(39): 41189-96. PMID: 15262962
5. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science. 2005; 307: 1098-01. PMID: 15718470
6. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18: 1926-45. PMID: 15314020
7. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006; 22(2): 159-68. PMID: 16603397
8. Bellacosa A, Kumar CC, Cristofano AD, Testa JR. Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting. Advances in Cancer Research. 2005; 94: 29-86. PMID: 16095999
9. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005; 8(3): 179-83. PMID: 16169463
10. Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, et al. A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome. The New England Journal of Medicine. 2011; 365: 611-19. 10.1056/NEJMoa1104017 PMID: 21793738
11. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8): 627-44. 10.1038/nrd2926 PMID: 19644473
12. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7): 489-501. 10.1038/nrc839 PMID: 12094235.
13. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: Variations on a theme. Oncogene. 2008; 27 (41): 5497-510. 10.1038/onc.2008.245 PMID: 18794884
14. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A. 1999; 96: 4240-45. PMID: 10200246
15. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009; 4: 127-50. 10.1146/annurev.pathol.4.110807.092311 PMID: 18767981
16. Wickenden JA, Watson CJ. Signalling downstream of PI3 kinase in mammary epithelium: A play in 3 Akts. Breast Cancer Res. 2010; 12(202): 1-9.
17. Blake JF, Xu R, Bencsik JR, Xiao D, Kallan NC, Schlachter S, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012; 55(18): 8110-27. PMID: 22934575
18. Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014; 9 (6): E100880. 10.1371/Journal.pone.0100880 PMID: 24978597
19. McCubrey JA, Steelman LS, Chapell WH, Abrams SL, Franklin RA, Montalto G, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget. 2012; 3(10): 1068-111. PMID: 23085539
20. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2010; 19(11): 1355-66. 10.1517/13543784.2010.520701 PMID: 20846000
21. Sommer EM, Dry H, Cross D, Guichard S, Davies BR, Alessi DR. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochem J. 2013; 452(3): 499-508. 10.1042/BJ20130342 PMID: 23581296
22. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011; 29 (35): 4688-95. 10.1200/JCO.2011.35.5263 PMID: 22025163
23. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell. 2007; 12 (2): 104-7. PMID: 17692802
24. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007; 448(7152): 439-44. PMID: 17611497
25. Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, et al. An Activating Mutation of AKT2 and Human Hypoglycemia. Science. 2011; 339: 474.
26. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 2012; 44: 941-45. 10.1038/ng.2329 PMID: 22729223
27. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA. AKT1 mutations in bladder cancer: Identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene. 2010; 29(1): 150-5. 10.1038/onc.2009.315 PMID: 19802009
28. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, et al. AKT1(E17K) in human solid tumours. Oncogene. 2008; 27(42): 5648-50. 10.1038/onc.2008.170 PMID: 18504432
29. Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J. E17K substitution in AKT1 in prostate cancer. Br J Cancer. 2010; 102(10): 1491-4. 10.1038/sj.bjc. 6605673 PMID: 20407443
30. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008; 99(8): 1265-8. 10.1038/sj.bjc.6604637 PMID: 18813315
31. Do H, Salemi R, Murone C, Mitchell PL, Dobrovic A. Rarity ofAKT1andAKT3E17K mutations in squamous cell carcinoma of lung. Cell Cycle. 2014; 9(21): 4411-2.
32. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer. 2008; 98(9): 1533-5. 10.1038/sj.bjc.6604212 PMID: 18392055
33. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, de Gisi S, et al. Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung. Cell Cycle. 2014; 7(5): 665-9.
34. Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer. 2009; 101(1): 145-8. 10.1038/sj.bjc.6605109 PMID: 19491896
35. Zilberman DE, Cohen Y, Amariglio N, Fridman E, Ramon J, Rechavi G. AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma. Cancer Genet Cytogenet. 2009; 191(1): 34-7. 10. 1016/j.cancergencyto.2009.01.009 PMID: 19389506
36. Sahm F, Bissel J, Koelsche C, Schweizer L, Capper D, Reuss D, et al. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol. 2013; 126(5): 757-62. 10.1007/s00401-013-1187-5 PMID: 24096618
37. Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb family receptors and interleukin-6. Br J Cancer. 1999; 79((5/6)): 707-17.
38. Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, et al. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res. 2013; 19(19): 5413-22. 10.1158/1078-0432.CCR-13-0884 PMID: 23888070
39. Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013; 19(7): 1760-72. 10.1158/1078-0432.CCR-12-3072 PMID: 23287563
40. Ashwell MA, Lapierre JM, Brassard C, Bresciano K, Bull C, Cornell-Kennon S, et al. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4, 5-b]pyridin-2-yl)pyridin-2-amines: Orally bioavailable, selective, and potent ATP-independent Akt inhibitors. J Med Chem. 2012; 55(11): 5291-310. 10. 1021/jm300276x PMID: 22533986
41. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, et al. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov. 2014; 4(3): 334-47. 10.1158/2159-8290.CD-13-0611 PMID: 24436048
42. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004; 91(2): 355-8. PMID: 15188009
43. Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 2008; 68(17): 6902-7. 10.1158/0008-5472.CAN-08-0770 PMID: 18757403
44. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009; 15(5): 429-40. 10.1016/j.ccr.2009.03.020 PMID: 19411071
45. Subik K, Lee J-F, Baxter L, Strzepak T, Costello D, Crowley P, et al. The expression patterns of eR, pR, HeR2, cK5/6, eGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast cancer cell Lines. Breast Cancer: Basic and Clinical Research. 2010; 4: 35-41.
46. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One. 2008; 3(8): E3065. 10.1371/Journal.pone.0003065 PMID: 18725974
47. Hermanto U, Zong CS, Wang L-H. The expression patterns of eR, pR, HeR2, cK5/6, eGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast cancer cell Lines. Oncogene. 2001; 20: 7551-62. PMID: 11709727
48. Raguz S, Yague E. Resistance to chemotherapy: New treatments and novel insights into an old problem. Br J Cancer. 2008; 99(3): 387-91. 10.1038/sj.bjc.6604510 PMID: 18665178
49. Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res. 2012; 18(24): 6784-91. 10.1158/1078-0432.CCR-12-1785 PMID: 23092874
50. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7): 1956-67. 10.1158/1535-7163.MCT-09-1012 PMID: 20571069
51. Lindhurst MJ, Yourick MR, Yu Y, Savage RE, Ferrari D, Biesecker LG. Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome. Sci Rep. 2015;In press(In press).
52. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: The growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007; 7(4): 127-34. 10.1007/s10238-007-0145-8 PMID: 18188524
53. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013; 73(1): 276-84. 10.1158/0008-5472.CAN-12-1726 PMID: 23066039
54. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene. 2011; 30(3222-44).
55. Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013; 19(13): 3533-44. 10.1158/1078-0432.CCR-12-3815 PMID: 23674493
56. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012; 18 (6): 1777-89. 10.1158/1078-0432.CCR-11-2123 PMID: 22422409
57. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, et al. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012; 18(20): 5816-28. 10.1158/1078-0432.CCR-12-1141 PMID: 22932669
58. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013; 3(7): 761-9. 10.1158/2159-8290.CD-13-0103 PMID: 23619167
59. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009; 15(16): 5049-59. 10.1158/1078-0432.CCR-09-0632 PMID: 19671852
60. Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, et al. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2012; 2(1): 56-67. 10.1158/2159-8290.CD-11-0170 PMID: 22328975
61. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A. 2007; 104(13): 5569-74. PMID: 17376864
62. Saleh M, Papadopoulos K, Arabnia A, Patnaik A, Stein RM, Chai F, et al. First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma. Eur J Cancer. 2014; 50(6): 104.